Evidence map›Paper›PMID 35725614›Full record

ArticleGlobalization and health2022

Leveraging WHO's Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model.

Solomon Owusu Sekyere, Ivana Škrnjug-Yudov, Ulysse Ateba Ngoa, Marcela Juárez Hernández, Onome T Abiri, James P Komeh, Markieu Janneh Kaira, Essa Marenah, Juwe Darnuwele Kercula, Keturah Smith and 3 more

Open access · goldAbstract read
In one paragraph

Article in Globalization and health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Solomon Owusu SekyerePaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany. Solomon.OwusuSekyere@pei.de.ORCID 0000-0002-1893-5475
Ivana Škrnjug-YudovPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.
Ulysse Ateba NgoaPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.
Marcela Juárez HernándezPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.
Onome T AbiriPharmacovigilance and Clinical Trials Department, Pharmacy Board of Sierra Leone, Central Medical Stores Compound, New England Ville, Freetown, Sierra Leone.
James P KomehPharmacovigilance and Clinical Trials Department, Pharmacy Board of Sierra Leone, Central Medical Stores Compound, New England Ville, Freetown, Sierra Leone.
Markieu Janneh KairaMedicines Control Agency, 54 Kairaba Avenue, K.S.M.D, Serrekunda, Gambia.
Essa MarenahMedicines Control Agency, 54 Kairaba Avenue, K.S.M.D, Serrekunda, Gambia.
Juwe Darnuwele KerculaMedicines Information & Clinical Trials, Liberia Medicines & Health Products Regulatory Authority (LMHRA), Monrovia, Liberia.
Keturah SmithMedicines Information & Clinical Trials, Liberia Medicines & Health Products Regulatory Authority (LMHRA), Monrovia, Liberia.
Olga RassokhinaPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.
Heidi MeyerPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.
Christoph ConradPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.
Paul Ehrlich Institut · DENational Public Health Institute of Liberia · LRSierra Leone Agricultural Research Institute · SL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA stable, well-functioning and integrated national medicines regulatory system is a core component of health systems resilient against infectious disease outbreaks. In many low- and middle-income countries, however, sizable gaps exist in the emergency preparedness framework of national regulatory authorities (NRAs). RegTrain-VaccTrain is a project of Germany Ministry of Health's Global Health Protection Programme that contributes to global efforts aimed at strengthening such regulatory systems by providing technical support and advice to partner NRAs. In this study, we probed the outputs of our capacity-strengthening activities for clinical trials oversight (CTO) to take stock of progress made and examine remaining priorities in order to provide specialized technical assistance in addressing them to improve operational readiness for emergencies.

methodData validated from NRA self-benchmarking results in 2017 and worksheet records of November 2021 were utilized to assess the emergency preparedness capacity for CTO in three VaccTrain partner NRAs (Liberia, Sierra Leone, The Gambia) before and after interventional capacity-strengthening partnership, using specific public health emergency-related (sub-)indicators of the WHO Global Benchmarking Tool.

resultsA generally weak and vulnerable structural framework for CTO characterized the emergency preparedness capacity in all three partner NRAs at baseline, thus putting their operational readiness for public health emergencies at risk. VaccTrain's collaborative work was successful at supporting individual NRAs to develop the full spectrum of operational structures (including (draft) regulations, guidelines, and standard operating procedures) required to improve regulatory preparedness. A gap in the formal approval and implementation of developed legal documents in two of three NRAs still remains. Notwithstanding, a robust emergency framework now exists and the NRAs stand better prepared to respond to (future) locally-concerning health emergencies, during which time clinical trials activity was observed to heighten.

conclusionsThese results exemplify a north-south capacity-strengthening partnership model that effectively contributes in developing structures to enhance regulatory oversight and support expeditious product development in response to crises. They further underscore the equally critical role local/national processes play in facilitating the full implementation of developed structures.

Indexed as

Disaster PlanningPublic HealthBenchmarkingEmergenciesGlobal HealthHumansWorld Health OrganizationCapacity strengtheningClinical trials oversightEmergency preparednessEvaluationPublic health emergenciesWHO GBT

Identifiers

PMID35725614
PMCPMC9207864
OpenAlexW4283172138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.